LTR Pharma recently announced the dosing of the first patients in the Phase II study of SPONTAN®, which is evaluating the safety, tolerability and pharmacokinetic profile of LTR Pharma’s rapid acting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results